ACAD (ACADIA Corp) Market Value to Book Value Ratio

Official company branding of ACADIA Pharma (ACAD)

ACADIA Pharmaceuticals (ACAD) is developing therapies for rare brain pathologies, leveraging the success of Nuplazid and Daybue alongside merger prospects. Financial stability is increasing due to regular payments from drug sales, with the indicator standing at 2.63. Production efficiency is ensured through logistics automation and external outsourcing. This chart of share price quotes confirms the current market dynamics of this biopharmaceutical business.

ACAD - acadia-pharm.com Market-to-Book Ratio over the range 07/04/2022 - 10/28/2026

Financial and market metric breakdowns for ACADIA Pharma (ACAD)

- price and consensus price forecast:
Stock Price ACADIA Pharmaceuticals|ACAD - Broker Consensus Forecast
- market capitalization data:
Market Value ACADIA Pharmaceuticals Inc|ACAD - Business Value
- book capitalization data:
Book Value per Share ACADIA Pharmaceuticals|ACAD - Total Stockholders' Equity|Market Cap to Net Assets Ratio acadia-pharm.com|ACAD - Company Total Assets
- debt and liquidity data:
Debt to Equity ACADIA Pharmaceuticals|ACAD - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity ACADIA Pharmaceuticals Inc|ACAD - Company Cumulative Debt|Debts to Book Capitalization ACADIA Pharmaceuticals Inc
Initial company analysis:ACADIA Pharmaceuticals - ACAD
Original product of ACADIA Pharmaceuticals Inc

Diversifying its portfolio of CNS disorder treatments allows ACADIA Pharmaceuticals (ACAD) to capitalize on its intellectual property through a market premium over net assets. This indicator measures the gap between market value and book value, reflecting investor expectations regarding future revenues from new drugs. By analyzing the price-to-book ratio trend, one can determine the degree of stock overvaluation and the existence of a safety margin during market shocks.

Competitor analysis

Market Capitalization to Book Value Ratio Biogen Inc.|NBIX (neurocrine.com) - Capitalization to Book Value Ratio|Market Value to Book Value Ratio Regencell Bioscience Holdings Limited (RGC)|Capitalization to Book Value Ratio Axsome|Xenon Pharmaceuticals Inc - Market Capitalization to Book Value Ratio|Market-to-Book Ratio Viking Therapeutics Corp VKTX|Market Cap to Net Assets Ratio SUPN (Supernus Pharmaceuticals)|catalystpharma.com - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Denali Therapeutics Inc. (DNLI)|HRMY: Market Value to Book Value|Market Value to Book Value Ratio BHVN|Amylyx Corp (AMLX) - Market-to-Book Ratio|TRVI (Trevi Therapeutics) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio praxismedicines.com|Market Capitalization to Book Value Ratio AVXL (Anavex Life Sciences Corp.)|Market Cap to Net Assets Ratio CeriBell Inc (CBLL)|Market Capitalization to Book Value Ratio PRTA (prothena.com)|Market Capitalization to Book Value Ratio Alector Inc. ALEC|Annexon, Inc. (ANNX) - Market Capitalization to Book Value Ratio|OMER - Capitalization to Book Value Ratio|Neurogene - Market Capitalization to Book Value Ratio|AC Immune S.A. (ACIU) - Market Capitalization to Book Value|VYGR (Voyager Pharma) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio Neumora Corp (NMRA)|Scilex Holding Company (SCLX) - Market Cap to Net Assets Ratio|Market Value to Book Value TVGN (tevogen.com)|Alpha Cognition Inc. (ACOG) - Market Value to Book Value Ratio|Market Capitalization to Net Assets cogrx.com CGTX|Market Capitalization to Book Value Ratio Inhibikase (IKT)|SAVA - Market Value to Book Value|ASRT: Market Capitalization to Book Value Ratio|COYA (Coya Therapeutics) - Market Capitalization to Book Value Ratio|VTGN - Market Value to Book Value Ratio|Market Value to Book Value OVID|Market Value to Book Value Ratio ABOS (Acumen Pharma)|Market Cap to Net Assets Ratio CervoMed Corporation (CRVO)|Market Capitalization to Book Value Ratio ATHE (Alterity Therapeutics Limited)|Market Capitalization to Book Value Ratio Clene Inc CLNN|PEPG: Market Capitalization to Book Value Ratio|JUNS - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio RLMD|Market-to-Book Ratio Annovis Bio Corporation|GRCE (Grace Therapeutics Inc) - Market Cap to Net Assets Ratio|Market Capitalization to Book Value Ratio fireflyneuro.com (AIFF)|Market Cap to Net Assets Ratio Klotho Neurosciences Inc|Market Cap to Book Value Multiple neurosense-tx.com (NRSN)|Market Capitalization to Book Value Ratio RVPH|Market Capitalization to Book Value MetaVia Inc. MTVA|NRXS: Market Capitalization to Book Value Ratio|HSDT - Market Cap to Net Assets Ratio|PASG: Market Capitalization to Book Value Ratio|NEUP (Neuphoria Therapeutics) - Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Minerva Neurosciences Corp|Market Value to Book Value Ratio ATHA|ADXN (Addex Therapeutics) - Market Value to Book Value Ratio|Market Capitalization to Book Value alzamend.com (ALZN)|Market Capitalization to Book Value Ratio CYCN (Cyclerion Therapeutics, Inc.)|Market Capitalization to Book Value Ratio Protagenic Therapeutics Inc. PTIX|KTTA: Market Capitalization to Book Value Ratio|CRGT - Market Cap to Net Assets Ratio|ATXI: Market Capitalization to Book Value Ratio|brainstorm-cell.com (BCLI) - Market Capitalization to Book Value Ratio|Market Capitalization to Book Value Ratio Cara Therapeutics (CARA)|Capitalization to Book Value Ratio CHRO|Market Value to Book Value Ratio Eliem Therapeutics ELYM|Capitalization to Book Value Ratio intracellulartherapies.com (ITCI)|LBPH: Market Capitalization to Book Value Ratio|MRNS - Market-to-Book Ratio|NKGen Biotech - Market Cap to Net Assets Ratio|NRBO: Market Capitalization to Book Value Ratio|Market Value to Book Value Ratio Sage Therapeutics, Inc SAGE|SNPX (Synaptogenix, Inc) - Market Value to Book Value|Market Value to Book Value Ratio TRVN (Trevena, Inc.)|Market-to-Book Ratio Vigil Neuro|Market Capitalization to Book Value Ratio WENA|Market Capitalization to Book Value Ratio Cerevel Therapeutics Inc (CERE)